Advanced search
Publication Cover
Bioengineered Volume 12, 2021 - Issue 1
Submit an article Journal homepage
1,830
Views
13
CrossRef citations to date
0
Altmetric
Research Paper

Long noncoding RNA MST1P2 promotes cervical cancer progression by sponging with microRNA miR-133b

Rongrong XuDepartment of Obstetrics and Gynecology, Dongtai Traditional Chinese Medicine Hospital, Dongtai City, Jiangsu Province, China
,
Xiaoyue ZhangDepartment of Obstetrics and Gynecology, Dongtai Traditional Chinese Medicine Hospital, Dongtai City, Jiangsu Province, China
,
Yan XuDepartment of Obstetrics and Gynecology, Dongtai Traditional Chinese Medicine Hospital, Dongtai City, Jiangsu Province, ChinaCorrespondence[email protected]
,
Junqin WangDepartment of Obstetrics and Gynecology, Dongtai Traditional Chinese Medicine Hospital, Dongtai City, Jiangsu Province, ChinaCorrespondence[email protected]
,
Zhihui LiDepartment of Obstetrics and Gynecology, Dongtai Traditional Chinese Medicine Hospital, Dongtai City, Jiangsu Province, China
&
Xiaoming CuiDepartment of Obstetrics and Gynecology, Dongtai Traditional Chinese Medicine Hospital, Dongtai City, Jiangsu Province, China
Pages 1851-1860 | Received 08 Feb 2021, Accepted 20 Apr 2021, Published online: 25 May 2021

References

  • Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1;136(5):E359–86. PMID: 25220842.
  • Cohen PA, Jhingran A, Oaknin A, et al. Cervical cancer. Lancet. 2019 2Jan 12;393(10167):169–182. PMID: 30638582.
  • Di J, Rutherford S, Chu C. Review of the cervical cancer burden and population-based cervical cancer screening in China. Asian Pac J Cancer Prev. 2015;16(17):7401–7407. PMID: 26625735.
  • Tsikouras P, Zervoudis S, Manav B, et al. Cervical cancer: screening, diagnosis and staging. J BUON. 2016 Mar-Apr;21(2):320–325. PMID: 27273940.
  • Marquina G, Manzano A, Casado A. Targeted agents in cervical cancer: beyond bevacizumab. Curr Oncol Rep. 2018 Apr 2;20(5):40. PMID: 29611060.
  • Van Werven FJ, Neuert G, Hendrick N, et al. Transcription of two long noncoding RNAs mediates mating-type control of gametogenesis in budding yeast. Cell. 2012;150(6):1170–1181.
  • Liu Y, Zhang R, Ying K. Long noncoding RNAs: novel links in respiratory diseases (review). Mol Med Rep. 2015;11(6):4025–4031.
  • Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res. 2017 Aug 1;77(15):3965–3981. PMID: 28701486.
  • Peng WX, Koirala P, Mo YY. LncRNA-mediated regulation of cell signaling in cancer. Oncogene. 2017 Oct 12;36(41):5661–5667. PMID: 28604750; PMCID: PMC6450570.
  • Li J, Meng H, Bai Y, et al. Regulation of lncRNA and its role in cancer metastasis. Oncol Res. 2016;23(5):205–217. PMID: 27098144.
  • Peng L, Yuan X, Jiang B, et al. LncRNAs: key players and novel insights into cervical cancer. Tumour Biol. 2016 Mar;37(3):2779–2788. PMID: 26715267.
  • Luan X, Wang Y. LncRNA XLOC_006390 facilitates cervical cancer tumorigenesis and metastasis as a ceRNA against miR-331-3p and miR-338-3p. J Gynecol Oncol. 2018 Nov;29(6):e95. PMID: 30207103; PMCID: PMC6189437.
  • Liu Y, Yang Y, Li L, et al. LncRNA SNHG1 enhances cell proliferation, migration, and invasion in cervical cancer. Biochem Cell Biol. 2018 Feb;96(1):38–43. PMID: 28930646.
  • Zeng J, Ma YX, Liu ZH, et al. LncRNA SNHG7 contributes to cell proliferation, invasion and prognosis of cervical cancer. Eur Rev Med Pharmacol Sci. 2019 Nov;23(21):9277–9285. PMID: 31773679.
  • Chen J, Li Y, Li Z, et al. LncRNA MST1P2/miR-133b axis affects the chemoresistance of bladder cancer to cisplatin-based therapy via Sirt1/p53 signaling. J Biochem Mol Toxicol. 2020 Apr;34(4):e22452. PMID: 32052927
  • Tutar Y. miRNA and cancer; computational and experimental approaches. Curr Pharm Biotechnol. 2014;15(5):429. PMID: 25189575.
  • Lu TX, Rothenberg ME. MicroRNA. J Allergy Clin Immunol. 2018 Apr;141(4):1202–1207. PMID: 29074454; PMCID: PMC5889965.
  • Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017 Mar;16(3):203–222. PMID: 28209991.
  • Li X, Deng S, Pang X, et al. LncRNA NEAT1 silenced miR-133b promotes migration and invasion of breast cancer cells. Int J Mol Sci. 2019 Jul 24;20(15):3616. Erratum in: Int J Mol Sci. 2020 Jul 30;21(15):PMID: 31344855; PMCID: PMC6695844.
  • Yang J, Wang H, Xu W, et al. Inhibition of miR-133b indicates poor prognosis and promotes progression of OSCC via SOX4. Eur Rev Med Pharmacol Sci. 2020 Dec;24(24):12717–12726. PMID: 33378019.
  • Chen X, Zhang Z, Ma Y, et al. LINC02381 promoted cell viability and migration via targeting miR-133b in cervical cancer cells. Cancer Manag Res. 2020 May 26;12:3971–3979. PMID: 32547232; PMCID: PMC7261661.
  • Yang D, Zhao D, Chen X. MiR-133b inhibits proliferation and invasion of gastric cancer cells by up-regulating FBN1 expression. Cancer Biomark. 2017 Jul 4;19(4):425–436. PMID: 28582847.
  • Zhang Q, Fan X, Xu B, et al. miR-133b acts as a tumor suppressor and negatively regulates EMP2 in glioma. Neoplasma. 2018;65(4):494–504.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.